WO2008056786A1 - Composition pour application cutanée ou par voie muqueuse - Google Patents
Composition pour application cutanée ou par voie muqueuse Download PDFInfo
- Publication number
- WO2008056786A1 WO2008056786A1 PCT/JP2007/071830 JP2007071830W WO2008056786A1 WO 2008056786 A1 WO2008056786 A1 WO 2008056786A1 JP 2007071830 W JP2007071830 W JP 2007071830W WO 2008056786 A1 WO2008056786 A1 WO 2008056786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecular weight
- composition
- skin
- alginic acid
- salt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 174
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 187
- 229920000615 alginic acid Polymers 0.000 claims abstract description 187
- 239000000783 alginic acid Substances 0.000 claims abstract description 171
- 229960001126 alginic acid Drugs 0.000 claims abstract description 171
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 166
- 150000003839 salts Chemical class 0.000 claims abstract description 86
- 210000004877 mucosa Anatomy 0.000 claims abstract description 66
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 42
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 42
- 210000004400 mucous membrane Anatomy 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 33
- 239000003889 eye drop Substances 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- 230000014759 maintenance of location Effects 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 abstract description 97
- 210000004027 cell Anatomy 0.000 abstract description 17
- 210000004927 skin cell Anatomy 0.000 abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 description 82
- 239000000243 solution Substances 0.000 description 25
- 238000009472 formulation Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 238000005227 gel permeation chromatography Methods 0.000 description 19
- -1 alginic acid salts Chemical class 0.000 description 17
- 230000007794 irritation Effects 0.000 description 17
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 16
- 229940072056 alginate Drugs 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- 238000012937 correction Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 229940012356 eye drops Drugs 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 238000000569 multi-angle light scattering Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 229920001218 Pullulan Polymers 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 238000011088 calibration curve Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 235000019423 pullulan Nutrition 0.000 description 8
- 239000004373 Pullulan Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229940100662 nasal drops Drugs 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000007923 nasal drop Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241001260563 Lessonia nigrescens Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000002997 ophthalmic solution Substances 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003221 ear drop Substances 0.000 description 3
- 229940047652 ear drops Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000004328 sodium tetraborate Substances 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- 239000000522 vaginal cream Substances 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960001983 magnesium aspartate Drugs 0.000 description 2
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229960000654 sulfafurazole Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 2
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940044959 vaginal cream Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YLXIPWWIOISBDD-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-NDAAPVSOSA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 101100517651 Caenorhabditis elegans num-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000024244 Chelis Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000304827 Durvillaea potatorum Species 0.000 description 1
- 241001392689 Ecklonia maxima Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241001598113 Laminaria digitata Species 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 241001512709 Lessonia <stramenopiles> Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001491708 Macrocystis Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000293085 Minaria Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N Pirenoxine Chemical compound C12=NC3=CC=CC=C3OC2=CC(=O)C2=C1C(=O)C=C(C(=O)O)N2 OKPNYGAWTYOBFZ-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000543375 Sideroxylon Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- WDTODOXBYLKKKB-UHFFFAOYSA-N Sulfamethoxazole sodium Chemical compound [Na+].CC1=CON=C1[N-]S(=O)(=O)C1=CC=C(N)C=C1 WDTODOXBYLKKKB-UHFFFAOYSA-N 0.000 description 1
- DYZJXZOQQRXDLE-UHFFFAOYSA-O Suplatast tosilate Chemical compound CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 DYZJXZOQQRXDLE-UHFFFAOYSA-O 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XQTARQNQIVVBRX-UHFFFAOYSA-N Tazanolast Chemical compound CCCCOC(=O)C(=O)NC1=CC=CC(C2=NNN=N2)=C1 XQTARQNQIVVBRX-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960003731 amlexanox Drugs 0.000 description 1
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- HZFGMQJYAFHESD-UHFFFAOYSA-M bromfenac sodium Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 HZFGMQJYAFHESD-UHFFFAOYSA-M 0.000 description 1
- 229960002716 bromfenac sodium Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
- 229960002165 carteolol hydrochloride Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
- 229940090570 dipivefrin hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- SZGZILRQIYNODJ-UHFFFAOYSA-L disodium;7,12-dihydroquinoxalino[3,2-b]phenazine-2,9-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC=C2N=C(C=C3C(NC4=CC=C(C=C4N3)S(=O)(=O)[O-])=C3)C3=NC2=C1 SZGZILRQIYNODJ-UHFFFAOYSA-L 0.000 description 1
- 229960001446 distigmine Drugs 0.000 description 1
- GJHSNEVFXQVOHR-UHFFFAOYSA-L distigmine bromide Chemical compound [Br-].[Br-].C=1C=C[N+](C)=CC=1OC(=O)N(C)CCCCCCN(C)C(=O)OC1=CC=C[N+](C)=C1 GJHSNEVFXQVOHR-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 1
- 229960002506 dorzolamide hydrochloride Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000003722 gum benzoin Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960004934 mebhydrolin Drugs 0.000 description 1
- FQQIIPAOSKSOJM-UHFFFAOYSA-N mebhydrolin Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 FQQIIPAOSKSOJM-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- QVRVXSZKCXFBTE-UHFFFAOYSA-N n-[4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)butyl]-2-(2-fluoroethoxy)-5-methylbenzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCNC(=O)C1=CC(C)=CC=C1OCCF QVRVXSZKCXFBTE-UHFFFAOYSA-N 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 1
- 229960004186 naphazoline nitrate Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 1
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- 229960001257 oxyquinoline sulfate Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- 229960005071 pirenoxine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 229940068988 potassium aspartate Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- VYGBQXDNOUHIBZ-UHFFFAOYSA-L sodium formaldehyde sulphoxylate Chemical compound [Na+].[Na+].O=C.[O-]S[O-] VYGBQXDNOUHIBZ-UHFFFAOYSA-L 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 1
- XTXYCJOBMKKQOW-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(2,6-dimethylpyrimidin-4-yl)azanide Chemical compound [Na+].CC1=NC(C)=CC([N-]S(=O)(=O)C=2C=CC(N)=CC=2)=N1 XTXYCJOBMKKQOW-UHFFFAOYSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229950001956 suplatast Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229950011558 tazanolast Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Definitions
- the present invention relates to a composition for application to skin or mucosa containing alginic acid and / or a salt thereof, which has reduced cytotoxicity to skin or mucosal cells. Furthermore, the present invention relates to a method for reducing the cytotoxicity of alginic acid and / or its salts.
- Alginic acid is partially cross-linked by a divalent or higher cation such as Ca 2+ ion and has a gelling (high viscosity) action. It is already known that it is a component that can be applied to mucous membranes (see Patent Document 1). When a preparation containing alginic acid is applied to the skin or mucous membrane, the preparation becomes gelled (high viscosity) on the skin or mucous membrane due to contact of a small amount of Ca 2+ ions present in the skin or mucous membrane with alginic acid. It has also been found to increase the retention of the formulation at the application site and to maintain the effect of the active ingredient.
- a divalent or higher cation such as Ca 2+ ion
- Patent Document 1 Japanese Patent Laid-Open No. 2002-332248
- Patent Document 2 JP 2006-517200 A
- Patent Document 3 Japanese Patent Laid-Open No. 2001-212223 Disclosure of the invention
- An object of the present invention is to provide a composition for application to skin or mucosa comprising alginic acid and / or a salt thereof, which has reduced toxicity to skin or mucous membrane and has higher safety. Furthermore, another object of the present invention is to provide a method for reducing the cytotoxicity of alginic acid and / or its salts.
- Alginic acid and / or a salt thereof which has been conventionally purified from kombu or the like and allowed to be applied to living organisms, has a mixture with a molecular weight of about 80 to 1000000. Among them, alginic acid and / or a salt thereof of a low molecular weight fraction having a molecular weight of 3500 or less is present in about 7 to 20% of the whole (peak area ratio by GPC method)! /.
- the low molecular weight fraction having a molecular weight of 3500 or less is cytotoxic to mucosal cells, but the higher molecular weight fraction is not cytotoxic to mucosal cells.
- the present invention has been completed by making further improvements based on force and knowledge.
- the present invention is the following composition for skin or mucosa.
- Item 1-1 A composition for application to skin or mucosa, comprising alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less.
- Item 1-2 The skin according to Item 1-1, wherein in the alginic acid and / or salt thereof, the fraction having a molecular weight of 380 or more and 3500 or less is 2.5% or less of the total amount of the fraction having a molecular weight of 380 or more. Skin or mucous membrane composition.
- the alginic acid and / or salt thereof is contained in an amount of 0.001 to 20% by weight based on the total amount of the composition.
- Item 1-4 The composition for skin or mucosa according to Item 1-1, which is a liquid.
- Item 1-5 The skin or mucous membrane according to Item 1-1, which is an ophthalmic composition, otolaryngological composition, oral composition, rectal composition, vaginal composition, or urethral composition. Application composition.
- Item 1-6 The composition for application to the skin or mucous membrane according to Item 1-1, which is an eye drop or an eye wash.
- the present invention is a method for reducing the cytotoxicity of alginic acid and / or a salt thereof described below.
- Item 2-1 A method for reducing the cytotoxicity of alginic acid and / or a salt thereof, comprising a step of substantially removing a low molecular weight fraction having a molecular weight of 3500 or less from alginic acid and / or a salt thereof.
- Item 2-2 In the step, the low molecular weight fraction is reduced from alginic acid and / or a salt thereof so that the fraction having a molecular weight of 380 or more and 3500 or less is 2.5% or less of the total amount of the fraction having a molecular weight of 380 or more.
- the present invention has the following uses.
- Item 3-1 Use of alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less for producing a composition for application to skin or mucosa.
- Item 3-2 Use according to Item 3-1, which is used for producing a composition for application to skin or mucosa with reduced cytotoxicity.
- Item 3-3 The use according to Item 3-1, wherein in the alginic acid and / or salt thereof, the fraction having a molecular weight of 380 or more and 3500 or less is 2.5% or less of the total amount of the fraction having a molecular weight of 380 or more.
- Item 3-4 The use according to Item 3-1, wherein the alginic acid and / or salt thereof is contained in an amount of 0.001 to 20% by weight based on the total amount of the composition applied to skin or mucosa.
- Item 3-5 The use according to Item 3-1, wherein the composition for application to skin or mucosa is a liquid.
- the composition applied to the skin or mucous membrane is an ophthalmic composition, an otolaryngological composition, an oral composition, a rectal composition, a vaginal composition, or a urethral composition. Use described in -1.
- Item 3-7 The use according to Item 3-1, wherein the composition for application to the skin or mucous membrane is an eye drop or an eye wash. for.
- the present invention has the following uses.
- Item 4-1 Use of alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less to avoid inducing cytotoxicity in a composition applied to skin or mucosa.
- Item 4-2. The use according to Item 4-1, wherein in the alginic acid and / or salt thereof, a fraction having a molecular weight of 380 or more and 3500 or less is 2.5% or less of a total amount of fractions having a molecular weight of 380 or more. for.
- Item 4-3 Use according to Item 4-1, which is used for producing a composition for application to skin or mucosa with reduced cytotoxicity.
- Item 4-4 The use according to Item 4-1, wherein the composition for application to skin or mucous membrane is a liquid.
- the composition for skin or mucous membrane application is an ophthalmic composition, an otolaryngological composition, an oral composition, a rectal composition, a vaginal composition, or a urethral composition.
- the present invention has the following uses.
- Alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less avoids inducing cytotoxicity in the skin or mucosa and is applied to the skin or mucosa. Use to increase the retention in the skin or mucous membrane of the active ingredient in the product.
- Item 5-2 The use according to Item 5-1, wherein in the alginic acid and / or salt thereof, a fraction having a molecular weight of 380 or more and 3500 or less is 2.5% or less of a total amount of fractions having a molecular weight of 380 or more. for.
- Item 5-3 Use according to Item 5-1, which is used for producing a composition for application to skin or mucosa with reduced cytotoxicity.
- Item 5-4 The use according to Item 5-1, wherein the composition for application to the skin or mucous membrane is a liquid.
- the composition applied to the skin or mucous membrane is an ophthalmic composition, an otolaryngological composition, or an oral composition.
- the use according to Item 5-1 which is a composition, rectal composition, vaginal composition, or urethral composition Item 5-6.
- the composition applied to the skin or mucous membrane is an eye drop or an eye wash, Use as described in Section 5-1.
- the present invention also relates to the use of alginic acid and / or a salt thereof listed below.
- Item 6-1 Alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less to avoid inducing cytotoxicity in the skin or mucous membrane.
- Item 6-2 Alginic acid and / or a salt thereof according to Item 6-1, wherein a fraction having a molecular weight of 380 or more and 3500 or less is 2.5% or less of a total amount of fractions having a molecular weight of 380 or more.
- Item 6-3 The alginic acid and / or salt thereof according to Item 6-1 wherein the composition for application to skin or mucosa is a liquid.
- the composition for application to the skin or mucous membrane is an ophthalmic composition, an otolaryngological composition, an oral composition, a rectal composition, a vaginal composition, or a urethral composition.
- Item 6-5 The alginic acid and / or salt thereof according to Item 6-1 wherein the composition for skin or mucosa is an eye drop or an eye wash.
- the present invention also relates to the use of alginic acid and / or a salt thereof listed below.
- Item 7-1 Molecular weight of 3500 or less to prevent the occurrence of cytotoxicity in the skin or mucous membrane and to increase the retention in the skin or mucous membrane of the active ingredient contained in the composition for applying to the skin or mucous membrane Alginic acid and / or a salt thereof substantially free from a low molecular weight fraction.
- Item 7-2 The alginic acid and / or salt thereof according to Item 7-1, wherein a fraction having a molecular weight of 380 or more and 3500 or less is 2.5% or less of a total amount of fractions having a molecular weight of 380 or more.
- Item 7-3 The alginic acid and / or salt thereof according to Item 7-1, wherein the composition for application to skin or mucosa is a liquid.
- the composition for application to the skin or mucous membrane is an ophthalmic composition, an otolaryngological composition, an oral composition, a rectal composition, a vaginal composition, or a urethral composition.
- the alginic acid and / or salt thereof according to Item 7-1, wherein the composition for application to the skin or mucous membrane is an eye drop or an eye wash.
- composition for application to the skin or mucous membrane of the present invention since the cell toxicity of alginic acid and / or its salt is remarkably reduced, it has high safety even for mucous membranes sensitive to toxicity. Can be used.
- Alginic acid and / or a salt thereof conventionally used has the property of easily causing precipitation in a solution, and is difficult to formulate.
- Alginic acid and / or a salt thereof used in the present invention According to this, the formation of precipitates can be suppressed. Therefore, the composition for application to the skin or mucosa of the present invention is advantageous in that it can be easily formulated as compared with the case of using alginic acid and / or a salt thereof.
- the composition for skin or mucosa of the present invention exhibits an excellent increase when it comes into contact with bodily fluids such as sweat and tears on the skin or mucous membrane due to the action of the alginic acid and / or its salt incorporated therein. It shows the effect of enhancing the viscosity effect and gel strength. Therefore, the composition for application to the skin or mucosa of the present invention avoids inducing cytotoxicity in the skin or mucosa, and the active ingredient blended in the composition for application to the skin or mucosa on the skin or mucosa. It is useful for increasing the retention and maintaining the effect of the active ingredient.
- the method for reducing the cytotoxicity of alginic acid and / or a salt thereof of the present invention can provide alginic acid and / or a salt thereof with reduced cytotoxicity to mucosal cells or skin cells. Toxicity is reduced and safety is high! / Useful for supplying raw materials to be blended in skin or mucous membrane composition.
- Alginic acid is a polysaccharide composed of mannuronic acid (hereinafter sometimes simply referred to as “M”) and guluronic acid (hereinafter sometimes simply denoted as “G”).
- M mannuronic acid
- G guluronic acid
- a block copolymer in which a polymer fraction (MM fraction), a homopolymer fraction of guluronic acid (GG fraction), and a fraction in which mannuronic acid and guluronic acid are randomly arranged (MG fraction) are arbitrarily combined. It is.
- alginic acid or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less is used.
- alginic acid that does not substantially contain a low molecular weight fraction having a molecular weight of 3500 or less means that a low molecular weight fraction having a molecular weight of 3500 or less is removed and a molecular weight is 3500 or less. Is inevitably left! /, Is included! /, Na! / Is alginic acid. More specifically, the total amount of fractions having a molecular weight of 380 or more (corresponding to a molecular weight of 380 or more when the GPC method is performed as “alginic acid substantially free of a low molecular weight fraction having a molecular weight of 3500 or less”).
- molecular weight of 3500 (The sum of peak areas corresponding to a molecular weight of 380 to 3500) (hereinafter simply referred to as “molecular weight of 3500 or less”).
- molecular weight of 3500 or less is alginic acid with a force of 3 ⁇ 4.5% or less.
- the alginic acid used in the composition for application to the skin or mucosa of the present invention preferably has a molecular weight of 3500 or less, preferably 0 to 2.0%. Less than, more preferably 0 to less than 1.5%, particularly preferably 0 to less than 1.0%.
- the alginic acid used in the present invention has a molecular weight higher than 3500! /
- the molecular weight fraction (high molecular weight fraction) is more than 97.5% of the total amount of the fraction having a molecular weight of 380 or more. Examples thereof preferably include 98.0 to 100%, more preferably 98.5 to 100%, particularly preferably 99.0 to 100%.
- the molecular weight of alginic acid and the ratio of the molecular weight of 3500 or less are determined by gel permeation chromatography (GPC method). Specific conditions are described in the reference examples.
- the constituent ratio (M / G ratio; molar ratio) of mannuronic acid to guluronic acid is not particularly limited.
- the M / G ratio In the range of 0.4 to 4.0 is widely used.
- the smaller the M / G ratio the easier the gelation of the composition tends to start.
- the M / G ratio is 2.5 or less, preferably Is preferably 2.0 or less, more preferably 1.6 or less, and particularly preferably 1.0 or less.
- the M / G ratio is a value calculated by fractionating alginic acid decomposed in block units and quantifying each, and specifically, A. Haug et al. ., Carbohyd. Res. 32 (1974), p.217-225.
- the ratio of the MM fraction, the GG fraction and the MG fraction is not particularly limited, and the use and shape of the composition for application to the skin or mucosa It can be selected as appropriate according to the conditions.
- the alginic acid salt used in the present invention is a form of alginic acid salt substantially free of a low molecular weight fraction having a molecular weight of 3500 or less, and is pharmacologically or physiologically. It is not particularly limited as long as it is permitted. Specific examples of the alginic acid salt include sodium salt, potassium salt, triethanolamine salt, ammonium salt and the like. These alginic acid salts may be used alone or in any combination of two or more.
- composition for skin or mucosa of the present invention is selected from alginic acid and its salts, as long as it does not substantially contain a low molecular weight fraction having a molecular weight of 3500 or less. These may be used alone or in any combination of two or more.
- alginic acid, sodium alginate and potassium alginate are water-soluble and are preferably used in the present invention.
- alginic acid is particularly preferable from the viewpoint of more advantageously obtaining the effects of the present invention and simplifying the production.
- Alginic acid and / or a salt thereof satisfying the above molecular weight range is a commercially available alginic acid and / or a salt thereof, or! Or alginate and / or a salt purified from a kombu according to a conventional method. It can be prepared by removing the fraction with a molecular weight of 3500 or less by subjecting it to filtration.
- commercially available alginic acid and / or a salt thereof, or alginic acid and / or a salt thereof purified from kombu according to a conventional method is added to a solution having a polarity lower than that of water, and the generated precipitate is recovered.
- alginic acid and / or a salt thereof satisfying the above molecular weight range can also be prepared.
- specific examples of the solution having a polarity lower than that of water include lower alcohols such as methanol and ethanol, organic solvents such as acetone, and a mixture thereof with water.
- examples of the kombu used as a raw material include Lessonia nigrescens from Chile, Lessonia a flavicans from Chile, West America Macrocystis. 2jrifera,
- the blending ratio of the above-mentioned alginic acid fraction is not particularly limited, and it depends on the type of mucosa to be applied, the form of the skin or mucosa application composition, etc. What is necessary is just to set suitably according to.
- the blending ratio of the above-mentioned alginic acid fraction (in terms of alginic acid weight) is usually 0.001 to 20% by weight, preferably 0.005 to 10% by weight, based on the total amount of the composition applied to the skin or mucous membrane.
- specific examples for each application of the composition applied to the skin or mucosa are as follows:
- an ophthalmic composition it is usually 0.001 to 1% by weight, preferably 0.005 to 1% by weight, more preferably 0.01 to 0.5% by weight, particularly preferably 0.01 to 0.2% by weight;
- compositions it is usually 0.001 to 10% by weight, preferably 0.01 to 5% by weight, more preferably 0.05 to 1% by weight;
- oral compositions it is usually 0.001 to 20% by weight, preferably 0.01 to 10% by weight, more preferably 0.01 to 5% by weight;
- a rectal, vaginal or urethral composition it is usually 0.001 to 10% by weight, preferably 0.005 to 5% by weight, more preferably 0.01 to 2% by weight;
- transdermal composition In the case of a transdermal composition, it is usually 0.001 to 20% by weight, preferably 0.01 to 10% by weight, more preferably 0.01 to 5% by weight.
- an active ingredient (pharmacologically active ingredient, physiologically active ingredient, etc.) can be blended in the composition for skin or mucosa of the present invention.
- the types of such components are not particularly limited, and examples include, for example, a decongestant component, an eye muscle modulator component, an anti-inflammatory component or an astringent component, an antiallergic component, vitamins, amino acids, an antibacterial component or a bactericidal agent Examples include components, sugars, polymer compounds or derivatives thereof, cellulose or derivatives thereof, local anesthetic components, glaucoma treatment components, and cataract treatment components.
- the pharmacologically active component and physiologically active component suitable in the present invention include the following components.
- Decongestant For example, ⁇ -adrenergic agonist, specifically epinephrine, hydrochloride Vinephrine, ephedrine hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, naphazoline hydrochloride, phenylephrine hydrochloride, methylephedrine hydrochloride, epinephrine hydrogen tartrate, naphazoline nitrate. These may be either d-form, 1-form or dl-form.
- Ocular muscle modulator component For example, cholinesterase inhibitor having an active center similar to acetylcholine, specifically, neostigmine methyl sulfate, tropicamide, and atenopine sulfate.
- Anti-inflammatory component or astringent component for example, zinc sulfate, zinc lactate, allantoin, epsilon monoaminocaproic acid, indomethacin, lysozyme chloride, silver nitrate, pranoprofen, sodium azulenesulfonate, dipotassium glycyrrhizinate, glycyrrhizic acid Diammonium, diclofenac sodium, bromfenac sodium, berberine chloride, benovelin sulfate, etc.
- astringent component for example, zinc sulfate, zinc lactate, allantoin, epsilon monoaminocaproic acid, indomethacin, lysozyme chloride, silver nitrate, pranoprofen, sodium azulenesulfonate, dipotassium glycyrrhizinate, glycyrrhizi
- Anti-allergic drug components for example, repo bastin, amlexanox, ibudilast, tazanolast, tranilast, istipendil, dipheterol, triprolidine, tripelenamine, tonziramine, mebhydroline, phenetadine, oxatomide, suplatast, cromogliclast Potassium etc.
- Vitamins for example, retinol acetate, retinol palmitate, pyridoxine hydrochloride, sodium flavin adenine dinucleotide, pyridoxal phosphate, cyanobalamine, panthenol, calcium pantothenate, sodium pantothenate, ascorbic acid, tocopherol acetate Nicotinic tocopherol, succinic tocopherol, succinic tocopherol calcium, ubiquinone derivatives, etc.
- Amino acids for example, aminoethylsulfonic acid (taurine), glutamic acid, creatine, sodium aspartate, potassium aspartate, magnesium aspartate, magnesium aspartate.potassium mixture, glutamic acid, sodium glutamate, dartamic acid
- glutamic acid sodium glutamate
- dartamic acid Magnesium, epsilon aminocaproic acid, glycine, alanine, arginine, lysine, y-aminobutyric acid, ⁇ ⁇ ⁇ -aminovaleric acid, sodium chondroitin sulfate, etc. These may be d-form, 1-form or dl-form.
- Antibacterial component or fungicide component for example, alkylpolyaminoethyldaricin, chloramphenicol, sulfamethoxazonole, sulfisoxazolinole, sulfamethoxazole Sodium, sulfisoxazol cetanolamine, sulfisoxazole monoethanolamine, sulfisomethol sodium, sulfisomidine sodium, ofloxacin, norfloxacin, repofloxacin, lomefloxacin hydrochloride, acyclovir, etc.
- Saccharides for example, monosaccharides, disaccharides, specifically glucose, maltose, trehalose, sucrose, cyclodextrin, xylitonor, sonorebitonore, mannitonor and the like.
- Polymer compound or derivative thereof for example, gum arabic, cara gum, xanthan gum, gyarub gum, guar gum, guayata fat, quince seed, dalman gum, tragacanth, benzoin gum, locust bean gum, casein, agar, dextrin, dextran, carrageenan, Gelatin, collagen, pectin, starch, polygalacturonic acid, chitin and its derivatives, chitosan and its derivatives, elastin, heparin, heparinoid, heparin sulfate, heparan sulfate, hyanoleronic acid, chondroitin sulfate, ceramide, polybulal alcohol (Completely or partially saponified product), polybulurpyrrolidone, polybullmethacrylate, polyacrylic acid, carboxybule polymer, polyethyleneimine, ribonucleic acid, deoxyli
- Cellulose or a derivative thereof for example, ethyl cellulose, hydroxyethyl cellulose, force noreoxy methino resenorelose, force nore oxy methino resenorelose sodium, force nore chelino resenorelose, nitrosenore Loin etc.
- Local anesthetic components for example, pro-power-in hydrochloride, lidocaine hydrochloride, and the like.
- Ingredients for treating glaucoma for example, isopropyl unoprostone, epinephrine, abraclozine hydrochloride, carteolol hydrochloride, dipivefrin hydrochloride, dorzolamide hydrochloride, pilocarpine hydrochloride
- Bunazosin hydrochloride bupranolol hydrochloride, betaxolol hydrochloride, befnolol hydrochloride, strength rubacol, levobanolol hydrochloride, epinephrine dipivalate, distigmine bromide, nipradinole, timoronole maleate, latanoprost, etc.
- Cataract treatment ingredients for example, dartathione, pirenoxine, sodium 5,12-dihydro azapentacene disulfonate, and the like.
- the blending ratios of various components are known in the fields of skin-applied preparations, mucosal-applied preparations, and the like, and the blending ratios of the above-described components in the skin or mucosa-applied composition of the present invention are Is appropriately set according to the dosage form of the composition applied to mucosa, the type of pharmacologically active ingredient or physiologically active ingredient, and the like.
- the blending ratio of the pharmacologically active ingredient or physiologically active ingredient is 0.0001 to 30% by weight, preferably 0.001 to 10% by weight based on the total amount of the composition applied to the skin or mucous membrane
- It can be selected from the range of about%.
- composition for skin or mucosa of the present invention various components and additives are appropriately selected according to conventional methods according to the use and form as long as the effects of the invention are not impaired.
- one or more of them can be used in combination.
- carriers aqueous solvent, aqueous or oily base, etc.
- various additives such as pH regulators, tonicity agents, chelating agents, buffering agents, and stabilizers.
- Carrier An aqueous solvent such as water or hydrous ethanol.
- Surfactant for example, polyoxyethylene (hereinafter abbreviated as POE) polyoxypropylene (hereinafter abbreviated as POP) block copolymer (specifically, poloxamer 407, etc.), Ethylenediamine POE- Nonionic interfaces such as POP block copolymer adducts (specifically, poloxamine), POE sorbitan monooleate, POE hydrogenated castor oil (specifically, POE (60) hydrogenated castor oil), polyoxyl stearate, etc.
- POE polyoxyethylene
- POP polyoxypropylene
- POP block copolymer specifically, poloxamer 407, etc.
- Ethylenediamine POE- Nonionic interfaces such as POP block copolymer adducts (specifically, poloxamine), POE sorbitan monooleate, POE hydrogenated castor oil (specifically, POE (60) hydrogenated castor oil), polyoxyl stearate, etc
- Glycine-type amphoteric surfactants such as alkyldiaminoethyl glycine
- Alkyl quaternary ammonium salts specifically, cationic surfactants such as benzalkonium chloride and benzethonium chloride, etc. The number of moles added is shown.
- Preservatives, bactericides, or antibacterial agents for example, alkyldiaminoethyldaricin hydrochloride, sodium benzoate, ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine darconate, chlorobutanol, sorbic acid, potassium sorbate , Sodium dehydroacetate, methyl noroxybenzoate, ethyl parabenzoate, propyl parabenzoate, butyl parabenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexamethylene Biguanide, etc.), Glow Kill (trade name, manufactured by Rhodia).
- alkyldiaminoethyldaricin hydrochloride sodium benzoate, ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine darconate, chlorobutanol, sorbic acid,
- pH regulator for example, hydrochloric acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, triethanolamine, monoethanolamine, diisopropanolamine, sulfuric acid, polyphosphoric acid, propionic acid, sulfur Acids, darconic acid, fumaric acid, lactic acid, tartaric acid, malic acid, succinic acid, darconolataton, ammonium acetate, etc.
- Isotonic agents for example, sodium bisulfite, sodium sulfite, potassium chloride, chlorinated sodium chloride, sodium chloride, magnesium chloride, potassium acetate, sodium acetate, sodium hydrogen carbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate , Sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, glycerin, propylene glycol, etc.
- Chelating agents for example, ascorbic acid, tetrasodium edetate, sodium edetate, and taenic acid.
- Buffer citrate buffer, acetate buffer, carbonate buffer, borate buffer, phosphate buffer, and the like. Specifically, citrate, sodium citrate, acetic acid, potassium acetate, sodium acetate, sodium hydrogen carbonate, sodium carbonate, boric acid, borax, phosphoric acid, phosphoric acid ninatrium phosphate, sodium dihydrogen phosphate, phosphoric acid Such as potassium dihydrogen.
- Stabilizers dibutylhydroxytoluene, trometamol, sodium formaldehyde sulphoxylate (Longalite), tocopherol, sodium pyrosulfite, monoethanolamine, monooleamine monostearate, glyceryl monostearate and the like.
- the dosage form of the composition for skin or mucosa of the present invention is not particularly limited, and is a liquid, suspension, ointment, cream, gel, lotion, patch, spray, aerosol, There are widely used dosage forms such as a varnishing agent. Among these, a liquid agent is preferable.
- composition for application to the skin or mucous membrane of the present invention can be produced according to a usual method by appropriately using an appropriate base or additive, depending on the dosage form and the like.
- the application target of the composition for applying skin or mucosa of the present invention may be either skin or mucosa, but is preferably mucosa.
- the mucosa to be applied is not particularly limited, and can be applied to various mucous membranes constituting a living body. Specifically, when the composition is applied to the mucous membrane, an ophthalmic composition applied to the ocular mucosa such as cornea and conjunctiva; an otolaryngological composition applied to the nasal cavity, ear cavity, etc .; gum, tongue , Lip, oral mucosa, etc.
- the composition can be used as a rectal composition applied to the rectum; a vaginal composition applied to the vagina; a urethral composition applied to the urethra, and the like.
- ophthalmic composition examples include eye drops (including eye drops and eye drops), and eye wash.
- Examples include eye wash (including eye wash, eye wash), ophthalmic ointment, outer contour lens mounting solution, and outer lens care agent (cleaning solution, preservative solution, disinfectant solution, multipurpose solution, etc.).
- the above eye drops and eye wash include eye drops and eye wash that can be used while wearing an outer contour lens.
- the contact lens includes all types of contact lenses such as hard contact lenses (including oxygen permeable hard contact lenses) and soft contact lenses.
- Specific examples of the otolaryngological composition include nasal drops (including nasal drops and nasal drops), nasal rinses (including nasal drops and nasal drops), and ear drops (including ear drops). Medicines and ear drops).
- Specific examples of the oral composition include oropharyngeal drugs and mouthwashes.
- the rectal composition include hemorrhoidal agents and suppositories.
- the vaginal composition include vaginal suppositories and vaginal creams.
- Specific examples of the urethral composition include a demulcent / surface anesthetic.
- the composition for skin or mucosa of the present invention is preferably used as an ophthalmic composition, more preferably as an eye drop or an eye wash.
- the ocular mucosa is known to be one of the mucous membranes that are susceptible to adverse effects due to cytotoxicity. It can be used with high safety without showing cytotoxicity even for ocular mucosa that is sensitive to the adverse effects of cytotoxicity.
- An eye wash is preferred because it cleans the ocular mucosa with a large amount of liquid.
- alginic acid and / or a salt thereof that is not cytotoxic to mucosal cells or skin cells by substantially removing a low molecular weight fraction having a molecular weight of 3500 or less from alginic acid and / or a salt thereof.
- Salt can be provided. Therefore, the present invention further includes, from another viewpoint, the cytotoxicity of alginic acid and / or a salt thereof, further comprising a step of substantially removing a low molecular weight fraction having a molecular weight of 3500 or less from alginic acid and / or a salt thereof.
- a method for reducing the above is provided. In the reduction method, alginic acid and / or so The means for substantially removing the low molecular weight fraction having a molecular weight of 3500 or less from the salt is as described in the section of “1. Composition for skin or mucosa”.
- alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less is a composition for application to skin or mucosa, particularly a composition for application to skin or mucosa with reduced cytotoxicity. It is useful for the production of Therefore, the present invention further provides use of alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less for the production of a composition for application to the skin or mucosa.
- the alginic acid and / or salt thereof cytotoxicity is exerted in the skin or mucous membrane composition containing alginic acid and / or salt thereof containing a low molecular weight fraction having a molecular weight of 3500 or less. It can be avoided. Therefore, the present invention further avoids the occurrence of cytotoxicity in the composition applied to skin or mucosa of alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less. Provide the use of.
- the present invention avoids the induction of cytotoxicity in the skin or mucous membrane of alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less, and the skin.
- the use of the active ingredient contained in the composition for applying to mucosa to enhance the retention in the skin or mucous membrane is provided.
- the present invention further provides alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less, in order to avoid inducing cytotoxicity in the skin or mucous membrane. .
- the alginic acid and / or salt thereof is formulated in the composition for application to the skin or mucosa while avoiding the occurrence of cytotoxicity in the skin or mucous membrane.
- the retention of the active ingredient on the skin or mucous membrane can be increased. Therefore, the present invention further avoids inducing cytotoxicity in the skin or mucous membrane, and increases the retention in the skin or mucous membrane of the active ingredient blended in the skin or mucosa applied composition. Therefore, alginic acid and / or a salt thereof substantially free of a low molecular weight fraction having a molecular weight of 3500 or less is provided.
- the molecular weight of alginic acid and the ratio of the molecular weight of 3500 or less were determined.
- eight kinds of pullulan standards with known molecular weights were used as molecular weight markers, and a calibration curve was obtained between the molecular weight of pullulan and the retention time by the GPC method.
- alginic acid (correction alginic acid sample) was subjected to the GPC method, and the provisional weight average molecular weight of alginic acid (correction alginic acid sample) was determined from the previously obtained calibration curve.
- alginic acid (correction alginic acid sample) is subjected to the GPC method, the weight average molecular weight is obtained, and the relational expression obtained from pullulan is obtained previously. to correct. Thereafter, using this corrected relational expression, the molecular weight of alginic acid and the ratio of the molecular weight of 3500 or less are obtained. Details are as shown below.
- MALS multi-angle light scattering detector
- the Genore permeation chromatography method uses a liquid chromatograph and measures under the following measurement conditions.
- Detector Differential refractive index detector or multi-angle light scattering detector (MALS)
- Multi-angle light scattering detector (MALS): Using DAWN-EOS type multi-angle light scattering detector
- Wavelength Set to 690nm (semiconductor laser).
- Pullulan standards available as molecular weight markers (more than 8 types of pullulans with a molecular weight in the range of 5900 to 788000) and glucose are each 0 ⁇ lw / v% moving bed as described in GPC measurement conditions above Dissolve the sample in 100 ml and subject each 100 L to the GPC method described below to determine the elution time.
- Logarithmic value of molecular weight M of each pullulan standard 1 og M is the y-axis and each elution time is the X-axis.
- the area number (An) of each section is divided by the provisional molecular weight of alginic acid (Mn assumption) of each section to calculate the provisional number of molecules of alginic acid (Nn assumption) of each section.
- the provisional weight average molecular weight (Mw assumption) of the correction alginic acid sample is calculated from the following equation (2).
- Equation 2 assumption ⁇ (N drunkassumption X Mn assumption X Mn assumption) / ⁇ (Nn assumption Mn assumption)
- the value of the weight average molecular weight (Mw assumption) of the temporary alginic acid calculated by Equation 2 is the same value as the true weight average molecular weight (Mw real) obtained by the GPC-MALS method in (3-3) above.
- the true molecular weight (Mn real) of alginic acid in each section is obtained by correcting the value of the provisional molecular weight (Mn assumption) of alginic acid.
- the value of b ′ is calculated so that the value calculated by substituting the following numerical values as the values of Mn assumption and Nn assumption in Equation 2 matches Mw real.
- the peak area of the chromatograph obtained by the GPC method is an automatic integration method of the following setting conditions using an Agilent 1100 series Agilent Chemstation manufactured by Agilent Technology, or a method equivalent thereto. It is calculated below. ,Initial setting
- the peak area of alginic acid having a molecular weight of 3500 or less is calculated as the peak area of alginic acid having a molecular weight of 380 or more and 3500 or less.
- the residue obtained on the filter paper is collected, dried at room temperature, and the acetone is distilled off to obtain alginic acid in the acetone-insoluble fraction (ie, alginic acid from which the low molecular weight fraction has been removed; Example 1). Got.
- the filtrate after filtration is collected, and acetone and water are distilled off under reduced pressure (100 to 150 mmHg, 25 ° C), so that alginate (ie, low molecular weight fraction of alginate) of the acetone-dissolved fraction is removed. Min; Comparative Example 2) was obtained.
- Liquid chromatograph [Agilent 1100 system (Agilent Technologies), controller / data processor: G2170AJ Chemstation, pump: G1311A, injection device: G1329A, detector: differential refractive index detector G1362A (set temperature 35 ° C), constant temperature]
- the ratio of the alginic acid obtained above (Example 1 and Comparative Example 1 2) having a molecular weight of 3500 or less was measured using the tank: G1316A] according to the conditions and methods described in the above Reference Example column.
- the ratio of the molecular weight of 3500 or less is determined according to the method described in the above Reference Example, by preparing a correction alginic acid sample, measuring the weight average molecular weight of the correction alginic acid sample, pullulan standard (Shodex P-82 , Using a calibration curve using Showa Denko), calculating the molecular weight of each peak detected by the GPC method of alginic acid (Example 1 and Comparative Example 1 2), and calculating the area of the peak Was determined by
- the ratio of each alginic acid (Example 1 and Comparative Example 12) having a molecular weight of 3500 or less was as follows.
- Usagi corneal epithelial cell line SIRC (ATCC number: CC L- 60) was prepared from 1 Ueru per 2 ⁇ 0 ⁇ 10 5 or 48-well microtiter first plate seeded with (co-made-learning Co.), prepared earlier The added alginate solution was added to a final alginate concentration of 0.1 or 1.0% (w / v), and then cultured under conditions of 37 ° C, 5% CO, and relative humidity 90%. An equal amount of cell culture medium was added to a well prepared without alginate solution as a control.
- Cell viability (%) 100 X (absorbance of each alginate solution added group Absorbance of medium supplemented with live cell detection reagent) I (absorbance of contrast control group Absorbance of medium supplemented with live cell detection reagent)
- An ophthalmic preparation of the following Formulation Example 1 was prepared using the alginic acid of Example 1.
- the ophthalmic solution is filtered through a membrane filter with a pore size of 0.22 m and then placed in a plastic container. Filled with fungus.
- Table 2 shows the obtained results. As a result, the feeling of use of the eye drop of Formulation Example 1 was good, and no one complained of irritation immediately after instillation, 5 minutes after instillation, or 10 minutes after instillation.
- alginic acid containing a low molecular weight fraction having a molecular weight of 3500 or less shows cytotoxicity to mucosal cells and can also cause irritation upon instillation.
- alginic acid from which a low molecular weight fraction having a molecular weight of 3500 or less is substantially removed has significantly low cytotoxicity to mucosal cells and does not cause irritation when instilled. It became clear that it was excellent in this point.
- a preparation (formulation example 411) having the composition shown in Table 3-5 was prepared using the alginic acid of Example 1.
- Formulation Example 4 Formulation Example 5
- Formulation Example 6 Formulation Example 7
- Ingredient Name (Unit: g / 100mL)
- Formulation Example 8 Formulation Example 9 Ingredient Name (Unit: g / 100mL) Contact Lens Disinfectant for Oropharyngeal Drug
- Example 1 Alkyl "Acinic Acid 0.1 0. 05 Gas” Lens; Sodium Rephonate-0.02 Potassium Chloride 0. 100-Sodium Chloride Chloride 0. 650-Sodium Hydrogen Phosphate 0.200 Mono diphosphate Sodium hydrogen 0. 015-Sodium hydrogen carbonate-0.2 Human "mouth oxyph'lohi. / Remechi) Rulose 0. 020-Sodium ethyleneamine tetraacetate-0.002
- FIG. 1 is a graph showing the results of a toxicity test on cells of alginic acid (Example 1 and Comparative Examples 1-2) in Test Example 1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008543147A JPWO2008056786A1 (ja) | 2006-11-10 | 2007-11-09 | 皮膚又は粘膜適用組成物 |
BRPI0718707-6A BRPI0718707A2 (pt) | 2006-11-10 | 2007-11-09 | Composição para aplicação em pele ou em mucosa |
GB0909307A GB2456476A (en) | 2006-11-10 | 2007-11-09 | Composition for skin or mucosal application |
US12/513,593 US20100069323A1 (en) | 2006-11-10 | 2007-11-09 | Composition for application to skin or mucosa |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006305995 | 2006-11-10 | ||
JP2006-305995 | 2006-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008056786A1 true WO2008056786A1 (fr) | 2008-05-15 |
Family
ID=39364596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/071830 WO2008056786A1 (fr) | 2006-11-10 | 2007-11-09 | Composition pour application cutanée ou par voie muqueuse |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100069323A1 (ja) |
JP (1) | JPWO2008056786A1 (ja) |
CN (1) | CN101534863A (ja) |
BR (1) | BRPI0718707A2 (ja) |
GB (1) | GB2456476A (ja) |
RU (1) | RU2009122167A (ja) |
WO (1) | WO2008056786A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010187659A (ja) * | 2009-01-20 | 2010-09-02 | Kao Corp | 精製アルギン酸又はその塩 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009086685A1 (zh) * | 2007-12-29 | 2009-07-16 | Dalian Yaweite Bioengineering Co., Ltd. | 低分子量海藻酸及其盐、应用、制法及药物组合物、食品 |
CN102085395A (zh) * | 2009-12-02 | 2011-06-08 | 日本乐敦制药株式会社 | 硅酮水凝胶隐形眼镜用眼科组合物 |
CN110693812A (zh) | 2012-06-13 | 2020-01-17 | 伊沃菲姆股份有限公司 | 用于增强避孕杀微生物剂有效性的组合物和方法 |
DK3082826T3 (da) * | 2013-12-19 | 2020-05-04 | Evofem Inc | Sammensætninger og fremgangsmåder til at inhibere inflammation og sygdomme under anvendelse af en alginsyre-baseret antimikrobiel forbindelse |
US9737609B2 (en) * | 2014-08-20 | 2017-08-22 | Professional Compounding Centers Of America (Pcca) | Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions |
EP3522879A4 (en) | 2016-10-04 | 2020-06-03 | Evofem, Inc. | METHOD OF TREATING AND PREVENTING BACTERIAL VAGINOSIS |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6351401A (ja) * | 1986-08-19 | 1988-03-04 | Nichiden Kagaku Kk | 多糖類の製造方法 |
JPH08311102A (ja) * | 1995-03-14 | 1996-11-26 | Shin Etsu Chem Co Ltd | 多糖類の精製方法 |
JP2000038342A (ja) * | 1998-05-18 | 2000-02-08 | Kyowa Yakuhin Kogyo Kk | 褥瘡・損傷皮膚修復用製剤 |
JP2002332249A (ja) * | 2001-03-08 | 2002-11-22 | Rohto Pharmaceut Co Ltd | アルギン酸含有組成物 |
JP2002332248A (ja) * | 2001-03-08 | 2002-11-22 | Rohto Pharmaceut Co Ltd | Gリッチなアルギン酸含有組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309380B1 (en) * | 1999-01-27 | 2001-10-30 | Marian L. Larson | Drug delivery via conformal film |
JP4017783B2 (ja) * | 1999-03-25 | 2007-12-05 | 焼津水産化学工業株式会社 | 昆布エキスの製造方法 |
-
2007
- 2007-11-09 CN CNA2007800418843A patent/CN101534863A/zh active Pending
- 2007-11-09 WO PCT/JP2007/071830 patent/WO2008056786A1/ja active Application Filing
- 2007-11-09 JP JP2008543147A patent/JPWO2008056786A1/ja active Pending
- 2007-11-09 RU RU2009122167/15A patent/RU2009122167A/ru not_active Application Discontinuation
- 2007-11-09 BR BRPI0718707-6A patent/BRPI0718707A2/pt not_active Application Discontinuation
- 2007-11-09 GB GB0909307A patent/GB2456476A/en not_active Withdrawn
- 2007-11-09 US US12/513,593 patent/US20100069323A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6351401A (ja) * | 1986-08-19 | 1988-03-04 | Nichiden Kagaku Kk | 多糖類の製造方法 |
JPH08311102A (ja) * | 1995-03-14 | 1996-11-26 | Shin Etsu Chem Co Ltd | 多糖類の精製方法 |
JP2000038342A (ja) * | 1998-05-18 | 2000-02-08 | Kyowa Yakuhin Kogyo Kk | 褥瘡・損傷皮膚修復用製剤 |
JP2002332249A (ja) * | 2001-03-08 | 2002-11-22 | Rohto Pharmaceut Co Ltd | アルギン酸含有組成物 |
JP2002332248A (ja) * | 2001-03-08 | 2002-11-22 | Rohto Pharmaceut Co Ltd | Gリッチなアルギン酸含有組成物 |
Non-Patent Citations (1)
Title |
---|
"Jikken Kagaku Koza, 20-2 Seibutsu Kagaku [II]", 14 December 2007 (2007-12-14), pages 1023 - 1025 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010187659A (ja) * | 2009-01-20 | 2010-09-02 | Kao Corp | 精製アルギン酸又はその塩 |
Also Published As
Publication number | Publication date |
---|---|
RU2009122167A (ru) | 2010-12-20 |
US20100069323A1 (en) | 2010-03-18 |
GB2456476A8 (en) | 2009-10-14 |
JPWO2008056786A1 (ja) | 2010-02-25 |
GB2456476A (en) | 2009-07-22 |
BRPI0718707A2 (pt) | 2014-01-07 |
CN101534863A (zh) | 2009-09-16 |
GB0909307D0 (en) | 2009-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5401043B2 (ja) | 眼科用組成物 | |
JP2017206547A (ja) | 眼科用組成物 | |
US20050271748A1 (en) | Compositions for treating hyperemia | |
WO2008056786A1 (fr) | Composition pour application cutanée ou par voie muqueuse | |
JPWO2008001872A1 (ja) | アルギン酸又はその塩を含有する眼科用組成物 | |
JP2007323010A (ja) | 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ | |
JP6373805B2 (ja) | コンタクトレンズ装着点眼液 | |
JP2018203791A (ja) | 眼科用アレルギー予防剤 | |
JP2010159249A (ja) | シリコーンハイドロゲルコンタクトレンズ用点眼剤 | |
JP5731046B1 (ja) | コンタクトレンズ用組成物 | |
JP2006241085A (ja) | 粘膜適用組成物 | |
JP5258329B2 (ja) | プラノプロフェン含有水性医薬組成物 | |
CA2346631C (en) | Antibacterial aqueous ophthalmic formulations containing ofloxacin and use of chitosan for solubilizing ofloxacin suspended in an aqueous media | |
JP2007277233A (ja) | 眼科用組成物 | |
JP6616137B2 (ja) | コンタクトレンズ用組成物 | |
JP2001278791A (ja) | 皮膚疾患処置用ゲル組成物 | |
JP6537223B2 (ja) | ソフトコンタクトレンズ用組成物 | |
JP2022029416A (ja) | ソフトコンタクトレンズ用組成物 | |
JP2021187857A (ja) | ソフトコンタクトレンズ用眼科組成物 | |
JP2006104114A (ja) | 粘膜適用組成物 | |
JP2023052196A (ja) | 摩擦によるストレス低減剤 | |
JP2016053015A (ja) | 眼科用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780041884.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07831561 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008543147 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12513593 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 0909307 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20071109 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0909307.1 Country of ref document: GB |
|
ENP | Entry into the national phase |
Ref document number: 2009122167 Country of ref document: RU Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07831561 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: PI0718707 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090508 |